HK1204992A1 - Topical ophthalmological pharmaceutical composition containing sunitinib - Google Patents

Topical ophthalmological pharmaceutical composition containing sunitinib

Info

Publication number
HK1204992A1
HK1204992A1 HK15105934.1A HK15105934A HK1204992A1 HK 1204992 A1 HK1204992 A1 HK 1204992A1 HK 15105934 A HK15105934 A HK 15105934A HK 1204992 A1 HK1204992 A1 HK 1204992A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
topical ophthalmological
containing sunitinib
Prior art date
Application number
HK15105934.1A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Bttger
Degenfeld Georges Von
Julia Freundlieb
Claudia Hirth-Dietrich
Joerg Keldenich
Jrgen Klar
Uwe Muenster
Andreas Ohm
Annett Richter
Bernd Riedl
Joachim Telser
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/062365 external-priority patent/WO2013000917A1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1204992A1 publication Critical patent/HK1204992A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15105934.1A 2012-06-25 2015-06-23 Topical ophthalmological pharmaceutical composition containing sunitinib HK1204992A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PK40512 2012-06-25
PCT/EP2012/062365 WO2013000917A1 (en) 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib
JOP20120170 2012-06-27
VE81612 2012-06-27
EP12198651 2012-12-20
PCT/US2013/044953 WO2013188283A1 (en) 2012-06-12 2013-06-10 Topical ophthalmological pharmaceutical composition containing sunitinib

Publications (1)

Publication Number Publication Date
HK1204992A1 true HK1204992A1 (en) 2015-12-11

Family

ID=49758933

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105934.1A HK1204992A1 (en) 2012-06-25 2015-06-23 Topical ophthalmological pharmaceutical composition containing sunitinib

Country Status (7)

Country Link
US (1) US20150174096A1 (de)
EP (1) EP2858628A1 (de)
JP (1) JP2017512748A (de)
CN (1) CN104582685A (de)
CA (1) CA2876311A1 (de)
HK (1) HK1204992A1 (de)
WO (1) WO2013188283A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117398350A (zh) 2014-12-15 2024-01-16 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
KR20240043821A (ko) 2015-06-06 2024-04-03 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
TWI700085B (zh) 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
MX2018014868A (es) 2016-06-02 2019-09-13 Cloudbreak Therapeutics Llc Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
EP3621654A4 (de) 2017-05-10 2021-02-17 Graybug Vision, Inc. Mikropartikel mit verlängerter freisetzung und suspensionen davon zur medizinischen therapie
KR20240028815A (ko) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1885336T3 (da) 2005-05-10 2009-05-25 Alcon Inc Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
CN101163473A (zh) * 2005-05-12 2008-04-16 辉瑞大药厂 使用舒尼替尼苹果酸盐的抗癌组合疗法
JP2008543775A (ja) 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
CA2631173A1 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment method
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
EP2098521A1 (de) * 2008-03-06 2009-09-09 Ratiopharm GmbH Kristalline Formen von N-[2-(diethylamino)-Ethyl]-5-[Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2,4-Dimethyl-1H-Pyroll-3-Carboxamid und Verfahren zu ihrer Herstellung
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CN102573477A (zh) 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물

Also Published As

Publication number Publication date
CN104582685A (zh) 2015-04-29
EP2858628A1 (de) 2015-04-15
US20150174096A1 (en) 2015-06-25
WO2013188283A8 (en) 2017-03-23
CA2876311A1 (en) 2013-12-19
WO2013188283A1 (en) 2013-12-19
JP2017512748A (ja) 2017-05-25

Similar Documents

Publication Publication Date Title
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
ZA201501930B (en) Pharmaceutical composition
HK1204564A1 (en) Topical ophthalmological pharmaceutical composition containing axitinib
HK1204992A1 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
EP2832730A4 (de) Mirabegronhaltige pharmazeutische zusammensetzung
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
HK1204563A1 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
IL266415A (en) Innovative pharmaceutical composition
HK1197176A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1210711A1 (en) Pharmaceutical composition comprising rebamipide
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1204289A1 (en) Topical ophthalmological pharmaceutical composition containing cediranib
ZA201502987B (en) Pharmaceutical composition
EP2883546A4 (de) Neue pharmazeutische zusammensetzung mit drei wirkstoffen mit differenzieller freisetzung
EP2897590A4 (de) Pharmazeutische zusammensetzung
EP2851074A4 (de) Analgetische pharmazeutische zusammensetzung
EP2851078A4 (de) Pharmazeutische zusammensetzung
EP2930175A4 (de) Neuartiges octahydropyridochinazolinderivat, pharmazeutische zusammensetzung damit sowie verwendungen des besagten derivats und der zusammensetzung
ZA201400751B (en) Pharmaceutical composition
AU2012904295A0 (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition